Related Experiment Video
Updated: May 30, 2026
09:33
A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
Published on: February 7, 2015
[Disease activity assessment in large vessel vasculitis].
L Magnani1, A Versari, D Salvo
1Struttura Complessa di Reumatologia, Arcispedale S. Maria Nuova, Viale Risorgimento 80, Reggio Emilia, Italy.
Reumatismo
|July 22, 2011
Summary
Assessing large vessel vasculitis (LVV) disease activity is difficult. While clinical indices and inflammatory markers correlate, positron emission tomography (PET) may offer greater sensitivity for detecting LVV activity.
Area of Science:
- Rheumatology
- Nuclear Medicine
- Immunology
Background:
- Assessing disease activity in large vessel vasculitis (LVV) presents significant clinical challenges.
- Current methods rely on clinical indices and inflammatory markers, but their accuracy can be limited.
Purpose of the Study:
- To compare the efficacy of inflammatory markers, clinical indices (Indian Takayasu Activity Score [ITAS], Kerr/National Institute of Health [Kerr/NIH]), and 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in assessing LVV disease activity.
Main Methods:
- Patients with LVV underwent assessment using ITAS, Kerr/NIH indices, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and FDG-PET scans.
- Interleukin-6 (IL-6) and its soluble receptor levels were also analyzed.
Main Results:
- FDG-PET results did not statistically correlate with ITAS or Kerr/NIH indices, showing increased uptake in patients with clinically inactive disease.
- Interleukin-6 and its soluble receptor levels also lacked statistical correlation with disease activity.
- Clinical indices (ITAS, Kerr/NIH) demonstrated significant correlation with each other and with inflammatory markers (ESR, CRP).
Conclusions:
- Clinical indices and inflammatory markers are valuable for assessing LVV disease activity.
- FDG-PET may be a more sensitive tool for detecting subclinical inflammation in LVV, despite a lack of correlation with current clinical scoring systems.
Related Concept Videos
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...